January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant

December 23, 2025

FDA OKs First Oral GLP-1 for Obesity

An oral GLP-1 option entered obesity care with outcomes similar to injectable therapy.

Conexiant

December 22, 2025

FDA Approves New Treatment for Lung Fibrosis

Nerandomilast becomes first preferential PDE4B inhibitor approved for PPF, slowing FVC decline in phase 3 trial

Conexiant

December 19, 2025

Who Decides Vaccine Evidence Now?

A fight over data standards at the FDA raises urgent questions about vaccine safety, ethics, and trust.

KFF Health News

December 19, 2025

Measles Cases Surge to 25-Year High

US faces threat to measles elimination status as respiratory virus season intensifies with emergence of vaccine-evading H3N2 subclade

Conexiant

December 18, 2025

When Immigration Fear Delays Care

Health systems report increased no-shows and unmet needs as immigration operations expand.

KFF Health News

December 15, 2025

PSVT Drug Approved for First Time in Decades

A self-administered intranasal calcium channel blocker enables treatment outside emergency department settings for acute paroxysmal supraventricular tachycardia episodes.

Conexiant

December 12, 2025

FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer

The FDA has approved pembrolizumab (Keytruda) or the subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) for the...

The ASCO Post

December 10, 2025

Is WHO Mpox Monitoring Window Too Short?

New data challenge WHO's 21-day observation window, as nearly one-quarter of infections develop rash after recommended surveillance period ends.

Conexiant